ORAGENICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
ORAGENICS, INC. (OGEN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $2.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-16
- ORAGENICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $2.00K, a 81.82% increase from fiscal 2024.
- ORAGENICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $1.10K, a 304.41% increase from fiscal 2023.
- ORAGENICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $272.00, a 55.56% decline from fiscal 2022.
- ORAGENICS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $612.00, a 99.98% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $2.00K 10-K · filed 2026-03-16 |
| 2024-12-31 | $1.10K 10-K · filed 2025-03-14 |
| 2023-12-31 | $272.00 10-K · filed 2025-03-14 |
| 2022-12-31 | $612.00 10-K · filed 2024-03-29 |
| 2021-12-31 | $2.82M 10-K · filed 2023-04-17 |
| 2020-12-31 | $740.00 10-K/A · filed 2022-07-29 |
| 2019-12-31 | $3.06K 10-K · filed 2021-03-01 |
| 2018-12-31 | $121.49K 10-K · filed 2020-03-04 |
| 2017-12-31 | $126.38K 10-K · filed 2019-03-29 |
| 2016-12-31 | $185.61K 10-K · filed 2018-02-16 |
| 2015-12-31 | $288.06K 10-K · filed 2017-02-27 |
| 2014-12-31 | $110.52K 10-K · filed 2016-03-30 |
| 2013-12-31 | $248.18K 10-K · filed 2015-02-27 |
| 2012-12-31 | $54.88K 10-K · filed 2014-02-28 |
| 2011-12-31 | $231.47K 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |